Partners

BioInvent’s partnering strategy is based on:

• Out-licensing opportunities with partners that can further develop and commercialize BioInvent’s proprietary pipeline assets.
• Research and development partnerships based on F.I.R.S.T™ and n-CoDeR®.
• Production of antibodies to external parties.

BioInvent has several licensing agreements and research collaborations with leading pharmaceutical companies:

	Exclusive licensing agreement with CASI Pharmaceuticals for BI-1206 in mainland China, Taiwan, Hong Kong and Macau.
	In June 2022, BioInvent and Exelixis entered into an option and license agreement focused on the identification and development of novel antibodies for use in IO therapeutics. The collaboration combines BioInvent’s cancer immunology and antibody biology expertise with Exelixis’ expertise and resources in antibody engineering and antibody-drug conjugate (ADC) technologies, and proven history of developing and commercializing oncology therapeutics. Target and antibody discovery will be performed using BioInvent’s proprietary n-CoDeR® antibody library and patient-centric F.I.R.S.T™ screening platform, which together allow for parallel target and antibody discovery.
	In December 2020, Pfizer selected antibodies directed at a previously-selected target under the cancer immunotherapy research collaboration. BioInvent is eligible for potential future development milestones in excess of USD 100 million if an antibody is developed through to commercialization, as well as up to double digit royalties.
	Co-developing (50/50 split of costs and profits) of oncolytic virus candidates for solid tumors, leveraging BioInvent’s n-CoDeR® and F.I.R.S.T™ platforms. Sharing of technology platforms, knowledge, and expertise.
	Two clinical trial collaboration and supply agreements with Merck, to evaluate the combination of BI-1206 and Keytruda® as well as BI-1808 and Keytruda®
	Antibody discovery partnerships
	Research collaborations